Le Lézard
Classified in: Health
Subjects: CCA, PER, FVT, MAT

Vireo Health Announces Participation at Benzinga Cannabis Capital Conference


MINNEAPOLIS, Oct. 13, 2020 /PRNewswire/ -- Vireo Health International, Inc. ("Vireo" or the "Company") (CNSX: VREO, OTCQX: VREOF), the science-focused, multi-state cannabis company with active operations in exclusively medical-only markets and licenses in seven states and the Commonwealth of Puerto Rico, today announced that Chief Medical Officer, Stephen Dahmer, M.D., will be participating at the Benzinga Cannabis Capital Conference on October 15, 2020.

Dr. Dahmer will serve on a panel discussion titled, "The Science Behind the Plant," at 11:00 am E.T., and he will also give a separate presentation at 3:45 pm E.T. on long-term opportunities in medical cannabis and highlight some of Vireo's clinical research trials that are currently underway. Interested parties may sign up to get a free spectator pass for these events at https://events.benzinga.com/register-ccc-october. For more information on the Benzinga conference, visit https://www.benzinga.com/events/cannabis/virtual/.

Dr. Dahmer, a board-certified primary care physician in New York, works with medical and educational organizations across the nation to conduct research which improves the scientific understanding of the benefits and safety of cannabis and its ability to treat a range of medical conditions. Dr. Dahmer leads Vireo's research partnerships with world-renowned organizations such as the Mayo Clinic, Park Nicollet, Montefiore Medical Center, Northwell Health, and MMJ.org.

Benzinga's virtual Cannabis Capital Conference is guaranteed to offer participants all the benefits of an immersive and robust in-person conference from any remote location. The conference will feature an interactive forum of live presentations from top CEOs, investors, and leaders in the cannabis space.

About Vireo Health International, Inc.

Vireo Health International, Inc. ("Vireo" or the "Company") is a physician-led cannabis company focused on bringing the best of technology, science, and engineering to the cannabis industry. Vireo manufactures proprietary, branded cannabis products in environmentally-friendly, state-of-the-art greenhouses and distributes its products through its growing network of Green GoodsTM retail dispensaries and through hundreds of third-party dispensaries in seven states. Vireo's team of more than 300 employees, led by scientists, engineers, and cultivation experts, is focused on efficiency and the creation of best-in-class products, while driving scientific innovation within the cannabis industry and developing meaningful intellectual property. Today, Vireo is licensed to grow and/or process cannabis in eight markets. The Company is operational in seven of those eight markets ? including the core markets of Arizona, Maryland, Minnesota, New Mexico, New York, Pennsylvania. The Company holds 32 total retail dispensary licenses, of which 13 are currently open for business. For more information about Vireo Health, please visit www.vireohealth.com.

Media Inquiries

Investor Inquiries

Albe Zakes

Sam Gibbons

Vice President, Corporate Communications

Vice President, Investor Relations

albezakes@vireohealth.com

samgibbons@vireohealth.com 

(267) 221-4800

(612) 314-8995

 

SOURCE Vireo Health International, Inc.


These press releases may also interest you

at 23:22
Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of its initial public offering of 9,750,000 shares of common stock, consisting of...

at 23:00
BioVaxys Technology Corp. ("BioVaxys" or the "Company") is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the "Private Placement")....

at 22:15
Icosavax, Inc. , a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the...

at 22:15
A June 26 article on The U.S. Sun reports on what it sees as the widespread misuse of the tool most associated with dental hygiene: the toothbrush. The article notes that many brush their teeth too roughly, causing lasting damage to the enamel of...

at 21:15
Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the pricing of its initial...

at 21:00
According to Technavio, incremental growth of USD 7.77 billion is expected in the ambulance services market during 2020-2024. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the ambulance services market in optimistic,...



News published on 13 october 2020 at 17:22 and distributed by: